Dopamine receptors and the dopamine hypothesis of schizophrenia

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Synapse

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry, Psychology

• Identifiers
  DOI 10.1002/SYN.890010203PMID 2905529
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN.

  2009cited by this paper
• Hypothesis: Bromocriptine lacks intrinsic dopamine receptor stimulating properties

  2005cited by this paper
• Dopamine D2 receptors in brain and anterior pituitary recognize agonist and antagonist actions of (−)-3-PPP

  2005cited by this paper
• [3H]205-501, a Non-catechol dopaminergic agonist, labels selectively and with high affinity dopamine D2 receptors

  2005cited by this paper
• Neurochemical effects of some ergot derivatives: A basis for their antiparkinson actions

  2005cited by this paper
• Perceptual capacity, functions of the corpus striatum and schizophrenia

  2005cited by this paper
• Mesolimbic dopamine function is not altered during continuous chronic treatment of rats with typical or atypical neuroleptic drugs

  2005cited by this paper
• Effects of dopamine on cyclic AMP concentration in the anterior pituitary glandin vitro

  2005cited by this paper
• Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats

  2004cited by this paper
• A clinical and pharmacodynamic evaluation of sulpiride

  2004cited by this paper
• Specific effect of haloperidol on dopamine turnover in the frontal cortex

  2004cited by this paper
• Dopaminergic behaviour stereospecifically promoted by the D1 agonist R-SK & F 38393 and selectively blocked by the D1 antagonist SCH 23390

  2004cited by this paper
• 3H-flupenthixol binding in post-mortem brains of schizophrenics: Evidence for a selective increase in dopamine D2 receptors

  2004cited by this paper
• [3H]-Domperidone labels only a single population of receptors which convert from high to low affinity for dopamine in rat brain

  2004cited by this paper
• Dopamine receptors in brain and periphery.

  1987cited by this paper
• Dopamine receptor elevation in denervated tissues

  1987cited by this paper
• Independent Dopamine D-1 and D-2 Receptor Regulation of Dopamine Agonist-induced Hyperactivity in 6-OHDA Lesioned Rats; but not in Normal Rats

  1986cited by this paper
• Dopamine D1 receptors characterized with [3H]SCH 23390. Solubilization of a guanine nucleotide-sensitive form of the receptor.

  1986cited by this paper
• Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment.

  1986cited by this paper
• Functional States of Dopamine Receptors

  1986cited by this paper
• The third biannual winter workshop on schizophrenia. Schladming, Austria, Jan 26-31, 1986.

  1986cited by this paper
• Structural abnormalities in the frontal system in schizophrenia. A magnetic resonance imaging study.

  1986cited by this paper
• Quantification of Neuroreceptors in the Living Human Brain. II. Inhibition Studies of Receptor Density and Affinity

  1986cited by this paper
• Dopaminergic mechanisms and motor function: characterization of D-1 and D-2 dopamine receptor interactions.

  1986cited by this paper
• Selectivity of agonists and antagonists at D2dopamine receptors compared to D1 and S2receptors

  1986cited by this paper
• Dopamine agonist induced self-multilative biting behavior in monkeys with unilateral ventromedial tegmental lesions of the brainstem: Possible pharmacological model for Lesch-Nyhan syndrome

  1986cited by this paper
• Photoaffinity labelling of dopamine D2 receptors by [3H]azidomethylspiperone

  1986cited by this paper
• Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET.

  1986cited by this paper
• Dopamine D2 receptors in schizophrenia studied in vivo.

  1986cited by this paper
• Dopamine D2 receptors photolabelled by [3H]azido-methylspiperone.

  1986cited by this paper
• Purification of bovine striatal dopamine D-2 receptor by affinity chromatography.

  1986cited by this paper
• Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics.

  1986cited by this paper
• Guanine nucleotide regulation of agonist interactions at [3H]SCH23390-labeled D1 dopamine receptors in rat striatum.

  1986cited by this paper
• Amygdala Dopamine Asymmetry in Schizophrenia: Neurochemical Evidence for a Left Temporal Lobe Dysfunction

  1986cited by this paper
• D-1 and D-2 dopamine receptor blockade: interactive effects in vitro and in vivo.

  1986cited by this paper
• Characterization of Sodium‐Dependent [3H]GBR‐12935 Binding in Brain: A Radioligand for Selective Labelling of the Dopamine Transport Complex

  1986cited by this paper
• Studies on the use of a novel affinity matrix, sepharose amine-succinyl-amine haloperidol hemisuccinate, ASA-HHS, for purification of canine dopamine (D2) receptor.

  1986cited by this paper
• Postmortem evidence of structural brain changes in schizophrenia. Differences in brain weight, temporal horn area, and parahippocampal gyrus compared with affective disorder.

  1986cited by this paper
• Identification of Dopamine “D3′’ and “D4′’ Binding Sites, Labelled with [3H]2‐Amino‐6,7‐Dihydroxy‐ 1,2,3,4‐ Tetrahydronaphthalene, as High Agonist Affinity States of the D1 and D2 Dopamine Receptors, Respectively

  1986cited by this paper
• Affinity chromatography of the anterior pituitary D2-dopamine receptor.

  1986cited by this paper
• The dopamine D1 receptor: partial purification of a digitonin-solubilized receptor-guanine nucleotide binding complex.

  1986cited by this paper
• Neuronal cholecystokinin and schizophrenia: pathogenic and therapeutic studies

  1986cited by this paper
• Inhibition of dopamine-stimulated cyclic AMP efflux from rat neostriatal slices by activation of mu- and delta-opioid receptors: a permissive role for D-2 dopamine receptors.

  1985cited by this paper
• Complete Conversion of Brain D2 Dopamine Receptors from the High‐ to the Low‐Affinity State for Dopamine Agonists, Using Sodium Ions and Guanine Nucleotide

  1985cited by this paper
• Unexpected potentiation by discriminant benzamide derivatives of stereotyped behaviours elicited by dopamine agonists in mice

  1985cited by this paper
• Dependence of dopamine receptor conversion from agonist high- to low-affinity state on temperature and sodium ions.

  1985cited by this paper
• Drug Potencies on Partially Purified Brain D2 Dopamine Receptors

  1985cited by this paper
• Dopamine receptor binding of C-11-3-N-methylspiperone in the caudate in schizophrenia and bipolar disorder: a preliminary report.

  1985cited by this paper
• Catecholamine - Receptors on Blood Cells of Untreated Schizophrenic Patients

  1985cited by this paper
• The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.

  1985cited by this paper
• Interactions of dopaminergic agonists and antagonists with dopaminergic D3 binding sites in rat striatum. Evidence that [3H]dopamine can label a high affinity agonist-binding state of the D1 dopamine receptor.

  1985cited by this paper
• D2 Dopamine Receptors in Calf Globus Pallidus: Agonist High‐ and Low‐Affinity Sites Not Regulated by Guanine Nucleotide

  1985cited by this paper
• Catalepsy induced by SCH 23390 in rats.

  1985cited by this paper
• Dopamine D2 receptor dissociation constant for spiperone: identical values using 3H-labeled agonist or 3H-labeled antagonist.

  1985cited by this paper
• Evidence that D-1 dopamine receptors contribute to the supersensitive behavioral responses induced by L-dihydroxyphenylalanine in rats treated neonatally with 6-hydroxydopamine.

  1985cited by this paper
• [3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease.

  1985cited by this paper
• Regulation of Anterior Pituitary D2 Dopamine Receptors by Magnesium and Sodium Ions

  1985cited by this paper
• Antistereotypic effects of dopamine D-1 and D-2 antagonists after intrastriatal injection in rats. pharmacological and regional specificity

  1985cited by this paper
• Interactions of dopamine agonists with brain D1 receptors labeled by 3H-antagonists. Evidence for the presence of high and low affinity agonist-binding states.

  1985cited by this paper
• Dopamine D2 receptor binding sites for agonists. A tetrahedral model.

  1985cited by this paper
• Binding of 3H-spiperone to human lymphocytes: a biological marker in schizophrenia?

  1985cited by this paper
• Behavioural stimulation is induced by separate dopamine D-1 and D-2 receptor sites in reserpine-pretreated but not in normal rats.

  1985cited by this paper
• SCH-23390 antagonism of a D-2 dopamine agonist depends upon catecholaminergic neurons.

  1985cited by this paper
• A comparison between centrifugation and filtration as a means to separate bound and unbound ligand during 3[H]-spiroperidol binding.

  1985cited by this paper
• Molecular mechanisms of receptor desensitization using the β-adrenergic receptor-coupled adenylate cyclase system as a model

  1985cited by this paper
• Photoaffinity labeling of the D2-dopamine receptor using a novel high affinity radioiodinated probe.

  1985cited by this paper
• Ventricular Enlargement in Schizophrenia

  1985cited by this paper
• Chronic haloperidol does not alter agonist affinity for dopamine receptors in vitro.

  1985cited by this paper
• Chemical and structural changes in the brain in patients with movement disorder.

  1985cited by this paper
• Selective D2 dopamine receptor agonists prevent catalepsy induced by SCH 23390, a selective D1 antagonist.

  1985cited by this paper
• Novel photoaffinity label for the dopamine D2 receptor: synthesis of 4-azido-5-iodo-2-methoxy-N-[1-(phenylmethyl)-4-piperidinyl] benzamide (iodoazidoclebopride, IAC) and the corresponding 125I-labeled analogue (125IAC).

  1985cited by this paper
• The electrical properties of isolated human prolactin-secreting adenoma cells and their modification by dopamine.

  1985cited by this paper
• Failure of SKF 38393‐A to relieve parkinsonian symptoms induced by 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine in the marmoset

  1985cited by this paper
• SCH 23390 may alter dopamine-mediated motor behaviour via striatal D-1 receptors.

  1985cited by this paper
• Quantitative Autoradiography of [3H]Indalpine Binding Sites in the Rat Brain: I. Pharmacological Characterization

  1985cited by this paper
• The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form.

  1985cited by this paper
• Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum.

  1985cited by this paper
• Dopamine D2 Receptors in the Anterior Pituitary: A Single Population Without Reciprocal Antagonist/Agonist States

  1985cited by this paper
• Dopamine D2 receptors selectively labeled by a benzamide neuroleptic: [3H]-YM-09151-2

  1985cited by this paper
• Sodium dependent [3H]cocaine binding associated with dopamine uptake sites in the rat striatum and human putamen decrease after dopaminergic denervation and in Parkinsons disease

  1985cited by this paper
• Photoaffinity labeling of D-2 dopamine binding subunits from rat striatum, anterior pituitary and olfactory bulb with a new probe, [3H]azidosulpride.

  1985cited by this paper
• Effect of the dopamine D-1 antagonist SCH 23390 on rotational behaviour induced by apomorphine and pergolide in 6-hydroxy-dopamine denervated rats.

  1985cited by this paper
• Inhibition of the Electrically Evoked Release of [3H]Acetylcholine in Rat Striatal Slices: An Experimental Model for Drugs that Enhance Dopaminergic Neurotransmission

  1985cited by this paper
• Comparison of Three 18F‐Labeled Butyrophenone Neuroleptic Drugs in the Baboon Using Positron Emission Tomography

  1985cited by this paper
• Rapid desensitization of presynaptic dopamine autoreceptors during exposure to exogenous dopamine.

  1985cited by this paper
• Chronic neuroleptic treatment increases D-2 but not D-1 receptors in rat striatum.

  1985cited by this paper
• Effects of pertussis toxin on D2-dopamine receptor in rat striatum: evidence for coupling of Ni regulatory protein with D2-receptor.

  1985cited by this paper
• Dopamine inhibition of anterior pituitary adenylate cyclase is mediated through the high-affinity state of the D2 receptor.

  1985cited by this paper
• Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography.

  1985cited by this paper
• [3H]SCH 23390 binding sites increase after chronic blockade of D-1 dopamine receptors.

  1985cited by this paper
• [3H]Threo‐(±)‐Methylphenidate Binding to 3,4‐Dihydroxyphenylethylamine Uptake Sites in Corpus Striatum: Correlation with the Stimulant Properties of Ritalinic Acid Esters

  1985cited by this paper
• SCH 23390, a selective D1 dopamine receptor blocker, enhances the firing rate of nigral dopaminergic neurons but fails to activate striatal tyrosine hydroxylase.

  1985cited by this paper
• Photoaffinity labeling and purification of solubilized D2 dopamine receptors.

  1985cited by this paper
• Differential effects of dopamine D-1 and D-2 agonists and antagonists in 6-hydroxydopamine-lesioned rats.

  1985cited by this paper
• Selective D-1 dopamine receptor increase following chronic treatment with SCH 23390.

  1985cited by this paper
• SKF 38393 and apomorphine modify locomotion and exploration in rats placed on a holeboard by separate actions at dopamine D-1 and D-2 receptors.

  1985cited by this paper
• Dopamine D2 receptors photolabeled by iodo-azido-clebopride.

  1985cited by this paper
• Conversion of dopamine D1 receptors from high to low affinity for dopamine.

  1985cited by this paper
• Amphetamine induced release of endogenous dopamine in vitro is not reduced following pretreatment with reserpine

  1985cited by this paper
• Frequency-dependent muscarinic receptor modulation of acetylcholine and dopamine release from rabbit striatum.

  1984cited by this paper

• ERVWE1 Impairs Mitochondrial Homeostasis and Promotes Neuronal Apoptosis via the miR-27b-3p/BNIP3 Axis in Schizophrenia.

  2026cites this paper
• Effects of the LINC00641/miR-323a-3p/EIF4G2 axis on behaviors and brain monoamine neurotransmitters in chronic unpredictable mild stress mice

  2025cites this paper
• Highly Sensitive Square Wave Adsorptive Stripping Voltammetric Determination of Dopamine in Human Plasma Using a Cytosine-Modified Pencil Graphite Electrode

  2025cites this paper
• Neuroinflammatory Loop in Schizophrenia, Is There a Relationship with Symptoms or Cognition Decline?

  2025cites this paper
• Structural Basis for D3/D4-Selective Antagonism of Piperazinylalkyl Pyrazole/Isoxazole Analogs

  2025cites this paper
• Pomgulated methionil (LY2140023) in schizophrenia patients: a systematic review and meta-analysis

  2025cites this paper
• Impact of D-Amino Acids in Schizophrenia

  2025cites this paper
• The fundamental disturbance (Grundstörung) of schizophrenia (Part 1): Acquiring a potent endophenotype, exploratory eye movement

  2025cites this paper
• Disruptions of the oxytocin system impair sociability and cognitive flexibility in a subchronic phencyclidine model of schizophrenia.

  2025cites this paper
• Apports des données en vie réelle à la sécurité des antipsychotiques chez l’enfant et l’adolescent

  2025cites this paper
• NMDAR dysfunction and the regulation of dopaminergic transmission in schizophrenia.

  2024cites this paper
• Bridging perspectives - A review and synthesis of 53 theoretical models of delusions.

  2024cites this paper
• The Underlying Neurobiological Mechanisms of Psychosis: Focus on Neurotransmission Dysregulation, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction

  2024cites this paper
• ZO-1 Serum Levels as a Potential Biomarker for Psychotic Disorder

  2024cites this paper
• HINT1 Gene Polymorphisms, Smoking Behaviour, and Personality Traits: A Haplotype Case-Control Study

  2024cites this paper
• Dopamine transmission in the tail striatum: Regional variation and contribution of dopamine clearance mechanisms

  2024cites this paper
• Neuromelanin-sensitive magnetic resonance imaging in the study of mental disorder: A systematic review.

  2024cites this paper
• Antipsychotic Drugs: A Concise Review of History, Classification, Indications, Mechanism, Efficacy, Side Effects, Dosing, and Clinical Application.

  2024cites this paper
• Ventrolateral prefrontal cortex in macaques guides decisions in different learning contexts

  2024cites this paper
• The Pathologic Roles and Therapeutic Implications of Ghrelin/GHSR System in Mental Disorders

  2024cites this paper
• A dopaminergic basis of behavioral control

  2024cites this paper
• The Role of Neuroglia in the Development and Progression of Schizophrenia

  2024cites this paper
• Bi‐directional and multi‐modal effects of dexamphetamine on spatial binding windows in healthy individuals

  2024cites this paper
• Exploring QSAR models for activity-cliff prediction

  2023cites this paper
• DRD4 VNTR 4/4 homozygosity as a genetic biomarker for treatment selection in patients with schizophrenia.

  2023cites this paper
• Pharmacological modulation of dopamine receptors reveals distinct brain-wide networks associated with learning and motivation in non-human primates

  2023cites this paper
• Unveiling the Differences in Signaling and Regulatory Mechanisms between Dopamine D2 and D3 Receptors and Their Impact on Behavioral Sensitization

  2023cites this paper
• Emerging trends in antipsychotic and antidepressant drug development: Targeting nonmonoamine receptors and innovative mechanisms

  2023cites this paper
• The Difficult Path to the Discovery of Novel Treatments in Psychiatric Disorders.

  2023cites this paper
• A clinical evaluation and management of Schizophrenia: A prospective study in Tertiary Care Hospital

  2023cites this paper
• Birth, cognitive and behavioral effects of intrauterine cannabis exposure in infants and children: A systematic review and meta-analysis.

  2023cites this paper
• Biological hypotheses, risk factors, and biomarkers of schizophrenia.

  2022cites this paper
• Antipsychotic Abuse, Dependence, and Withdrawal in the Pediatric Population: A Real-World Disproportionality Analysis

  2022cites this paper
• Flexible Glassy Carbon Multielectrode Array for In Vivo Multisite Detection of Tonic and Phasic Dopamine Concentrations

  2022cites this paper
• Organic Electrochemical Transistor with Molecularly Imprinted Polymer-Modified Gate for the Real-Time Selective Detection of Dopamine

  2022cites this paper
• Limbic Circuit and Lesions

  2022cites this paper
• Effect of Formulation Variables on Fabrication of Risperidone Loaded Nanoparticles for Sustained Drug Delivery

  2022cites this paper
• Disentangling early and late onset of psychosis in women: identifying new targets for treatment

  2022cites this paper
• Olanzapine-Induced Parkinsonism and Akathisia: A Case Report

  2022cites this paper
• Abnormal synaptic plasticity and impaired cognition in schizophrenia

  2022cites this paper
• Modulation of stimulated dopamine release in rat nucleus accumbens shell by GABA in vitro: Effect of sub‐chronic phencyclidine pretreatment

  2021cites this paper
• Roles of the Functional Interaction between Brain Cholinergic and Dopaminergic Systems in the Pathogenesis and Treatment of Schizophrenia and Parkinson’s Disease

  2021cites this paper
• The chemical interaction between the neurotransmitter dopamine and the antipsychotic drugs olanzapine and quetiapine

  2021cites this paper
• Differential Distribution of D4 and D2 Dopamine Receptors in Rat Brain: An Autoradiographic Study Using [3H]YM-09151-2 and [3H]Raclopride

  2021cites this paper
• 3D fuzzy graphene microelectrode array for dopamine sensing at sub-cellular spatial resolution.

  2021cites this paper
• The Yale Undergraduate Research Journal The Yale Undergraduate Research Journal

  2021cites this paper
• The critical balance between dopamine D2 receptor and RGS for the sensitive detection of a transient decay in dopamine signal

  2021cites this paper
• Target selection for deep brain stimulation in treatment resistant schizophrenia.

  2021cites this paper
• Investigating the association between common DRD2/ANKK1 genetic polymorphisms and schizophrenia: a meta-analysis

  2021cites this paper
• MK-801-induced behavioral and dopaminergic responses in the shell part of the nucleus accumbens in adult rats are disrupted after neonatal blockade of the ventral subiculum

  2021cites this paper
• Pharmaco-Magnetic Resonance as a Tool for Monitoring the Medication-Related Effects in the Brain May Provide Potential Biomarkers for Psychotic Disorders

  2021cites this paper
• The Impact of the Combined Administration of 1MeTIQ and MK-801 on Cell Viability, Oxidative Stress Markers, and Glutamate Release in the Rat Hippocampus

  2021cites this paper
• The coming together of allosteric and phosphorylation mechanisms in the molecular integration of A2A heteroreceptor complexes in the dorsal and ventral striatal-pallidal GABA neurons

  2021cites this paper
• Psychopharmacology: A Brief Overview of Its History

  2020cites this paper
• Striatal indirect pathway mediates action switching via modulation of collicular dynamics

  2020cites this paper
• Prefrontal inhibition of neuronal Kv7 channels enhances prepulse inhibition of acoustic startle reflex and resistance to hypofrontality

  2020cites this paper
• Schizophrenia: Current Hypotheses, Treatments, and Future Directions

  2020cites this paper
• Clozapine

  2020cites this paper
• Antipsychotics Circa 2020: What Are We Thinking?

  2020cites this paper
• Risperidone

  2020cites this paper
• Animal Models for Brain Research

  2020cites this paper
• Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia.

  2020cites this paper
• Modulating NMDA receptors to treat MK-801-induced schizophrenic cognition deficit: effects of clozapine combining with PQQ treatment and possible mechanisms of action

  2020cites this paper
• Dopamine Receptor Activation Modulates the Integrity of the Perisynaptic Extracellular Matrix at Excitatory Synapses

  2020cites this paper
• Multiple Adenosine-Dopamine (A2A-D2 Like) Heteroreceptor Complexes in the Brain and Their Role in Schizophrenia

  2020cites this paper
• Enzyvitands: evolvable biosynthetic and colorimetric chalices

  2020cites this paper
• Serotonin and schizophrenia

  2020influential citation
• Conventional and novel pharmacological approaches to treat dopamine-related disorders. Focus on Parkinson's disease and schizophrenia.

  2020cites this paper
• Visual Hallucinations and the Role of Medications in Parkinson's Disease: Triggers, Pathophysiology, and Management.

  2020cites this paper
• Preadolescent dopamine receptor antagonism increases postadolescent reward-related operant behaviors that may depend on dopamine receptor hypersensitivity.

  2020cites this paper
• On the profiling of autoantibodies in psychiatric disorders

  2019cites this paper
• Dopamine in psychiatry: a historical perspective

  2019cites this paper
• Long-Term Effects of Juvenile NMDAr or DAr Antagonism on Adolescent Reward-Related Neurobehavioral Outcomes

  2019cites this paper
• Dopamine manipulations modulate paranoid social inferences in healthy people

  2019cites this paper
• Acute and long-term effects of haloperidol on surgery-induced neuroinflammation and cognitive deficits in aged rats

  2019cites this paper
• Dopamine modulates paranoid social inferences: a double-blind, within-subject, randomised control study in a healthy population.

  2019cites this paper
• MDGA1-deficiency attenuates prepulse inhibition with alterations of dopamine and serotonin metabolism: An ex vivo HPLC-ECD analysis.

  2019cites this paper
• The effects of electrical stimulation mediated by conductive polymers on in vitro models of schizophrenia

  2019cites this paper
• Detecting local genetic correlations with scan statistics

  2019cites this paper
• Schizophrenia in a genomic era: a review from the pathogenesis, genetic and environmental etiology to diagnosis and treatment insights

  2019cites this paper
• Functional Magnetic Resonance Spectroscopy in First-Episode Schizophrenia: Measuring Glutamate and Glutathione Dynamics at 7-Tesla

  2019cites this paper
• Serotonin Receptors as the Therapeutic Target for Central Nervous System Disorders

  2019cites this paper
• Dopamine D 2 Partial Agonists – Discovery, Evolution, and Therapeutic Potential

  2019cites this paper
• From Schizophrenia Genetics to Disease Biology: Harnessing New Concepts and Technologies

  2019cites this paper
• Dopamine modulates the integrity of the perisynaptic extracellular matrix at excitatory synapses

  2019cites this paper
• l-Arginine metabolism before and after 10 weeks of antipsychotic treatment in first-episode psychotic patients.

  2019cites this paper
• Regulatory Role of lncRNA NONHSAT089447 in the Dopamine Signaling Pathway in Schizophrenic Patients

  2019cites this paper
• Neurochemical evidence that cysteamine modulates amphetamine-induced dopaminergic neuronal activity in striatum by decreasing dopamine release: an in vivo microdialysis study in freely moving rats.

  2019cites this paper
• Pharmacological analysis of the mechanisms underlying seizure induction mediated by nicotinic acetylcholine receptors (ニコチン性アセチルコリン受容体を介するけいれん発作発現メカニズムの薬理解析)

  2018cites this paper
• DNA methylation and antipsychotic treatment mechanisms in schizophrenia: Progress and future directions

  2018cites this paper
• Brain Dopamine Transmission in Health and Parkinson's Disease: Modulation of Synaptic Transmission and Plasticity Through Volume Transmission and Dopamine Heteroreceptors

  2018cites this paper
• Classics in Chemical Neuroscience: Risperidone.

  2018cites this paper
• Accelerated alcohol use across adolescence predicts early adult symptoms of alcohol use disorder via reward-related neural function

  2018cites this paper
• Transcriptomic signatures of schizophrenia revealed by dopamine perturbation in an ex vivo model

  2018cites this paper
• Classics in Chemical Neuroscience: Chlorpromazine.

  2018cites this paper
• Metabotropic glutamate receptor modulation of dopamine release in the nucleus accumbens shell is unaffected by phencyclidine pretreatment: In vitro assessment using fast-scan cyclic voltammetry rat brain slices.

  2018cites this paper
• Chlorpromazine versus thiothixene for people with schizophrenia

  2017cites this paper
• The neural underpinnings of cognitive flexibility and their disruption in psychotic illness.

  2017cites this paper
• Influence of Dopamine-Related Genes on Neurobehavioral Recovery after Traumatic Brain Injury during Early Childhood

  2017cites this paper
• Immersion in altered experience: An investigation of the relationship between absorption and psychopathology.

  2017cites this paper